Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.
How this was made
The 30-second read
Why it matters
The settlement secures Aurinia's revenue stream while limiting Teva's generic launch, influencing both stocks.
Market read
The legal settlement directly impacts Aurinia's exclusivity period and stock price, while constraining Teva's generic entry.
What to watch
Potential regulatory delays for the generic could further affect Teva's timeline.
Background
Aurinia's Lupkynis is the first FDA‑approved oral therapy for lupus nephritis, generating $153 M in sales in H1 2026.
Ticker impact
Aurinia settled its voclosporin patent lawsuit with Teva, delaying generic entry until Dec 2036 and causing a 6% stock rise.
Potential upside of 5‑8% over the next 3‑6 months if no further challenges arise.
Extended exclusivity reduces competitive pressure and aligns with recent sales growth.
Teva agreed to the settlement, accepting a launch delay for its generic voclosporin until Dec 2036.
Possible short‑term downside of 2‑4% as launch timeline is pushed back.
Delayed entry reduces immediate market opportunity for the generic product.
Market effects
Biotech sector may see reduced generic pressure on lupus therapies.
U.S. biotech investors could favor Aurinia over peers.
Limited to companies with similar autoimmune drug pipelines.
Counterpoint
If Teva successfully challenges the patents later, Aurinia's exclusivity could be shortened.
Key entities
- CompanyAurinia Pharmaceuticals
Biotech firm with Lupkynis for lupus nephritis.
- CompanyTeva Pharmaceuticals
Generic drug manufacturer seeking to launch voclosporin.
